Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

9.570 USD -0.640 (-6.27%)
Streaming Delayed Price Updated: 10:49 AM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biocryst Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 201
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Immunomedics, Inc.... 
From GlobeNewswire News Releases
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. 
From GlobeNewswire News Releases
BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of... 
From GlobeNewswire News Releases
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies London Healthcare Conference on Thursday, November 15, 2018 at 3:00 a.m. ET and the Piper... 
From GlobeNewswire News Releases
BioCryst Reports Third Quarter 2018 Financial Results
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2018. 
From GlobeNewswire News Releases
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma &... 
From GlobeNewswire News Releases
BioCryst to Report Third Quarter 2018 Financial Results on November 6
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2018 financial results on Tuesday, November 6, 2018. 
From GlobeNewswire News Releases
Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ardelyx, Inc.... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, October 2, 2018 at 1:40 p.m.... 
From GlobeNewswire News Releases
BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an... 
From GlobeNewswire News Releases
CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Centers for Disease... 
From GlobeNewswire News Releases
CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo... 
From GlobeNewswire News Releases
BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Baird Global Healthcare Conference in New York on Thursday, September 6, 2018 at 2:35 p.m. ET. 
From GlobeNewswire News Releases
New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 20
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cincinnati Bell Inc... 
From GlobeNewswire News Releases
BioCryst Reports Second Quarter 2018 Financial Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2018. 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the... 
From GlobeNewswire News Releases
U.S. FDA Grants Fast Track Designation for BioCryst’s BCX7353
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has been... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, offered at a price to the public of $5.50 per... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Commences Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is... 
From GlobeNewswire News Releases
BioCryst to Announce Second Quarter 2018 Financial Results on August 7
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2018 financial results will be reported on Tuesday, August 7, 2018. 
From GlobeNewswire News Releases
BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that results from the Phase 2,... 
From GlobeNewswire News Releases
Drug Developers Expecting Significant Clinical and Economic Benefits by Targeting Newest Drug Therapies
From PR Newswire
BioCryst Provides Update on Strategy, Pipeline and Outlook
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an... 
From Business Wire News Releases
BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst”) today announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”)... 
From Business Wire News Releases
BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has reached... 
From GlobeNewswire News Releases
Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.
Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BCRX") expressing its continued opposition to BCRX's proposed merger with Idera... 
From PR Newswire
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the JMP Securities Life Sciences... 
From GlobeNewswire News Releases
BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today issued an... 
From Business Wire News Releases
BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced the presentation of additional... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account